| Literature DB >> 24206430 |
Chih-Chuan Yu1, Alessia Fornoni, Astrid Weins, Samy Hakroush, Dony Maiguel, Junichiro Sageshima, Linda Chen, Gaetano Ciancio, Mohd Hafeez Faridi, Daniel Behr, Kirk N Campbell, Jer-Ming Chang, Hung-Chun Chen, Jun Oh, Christian Faul, M Amin Arnaout, Paolo Fiorina, Vineet Gupta, Anna Greka, George W Burke, Peter Mundel.
Abstract
Abatacept (cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion protein [CTLA-4-Ig]) is a costimulatory inhibitor that targets B7-1 (CD80). The present report describes five patients who had focal segmental glomerulosclerosis (FSGS) (four with recurrent FSGS after transplantation and one with primary FSGS) and proteinuria with B7-1 immunostaining of podocytes in kidney-biopsy specimens. Abatacept induced partial or complete remissions of proteinuria in these patients, suggesting that B7-1 may be a useful biomarker for the treatment of some glomerulopathies. Our data indicate that abatacept may stabilize β1-integrin activation in podocytes and reduce proteinuria in patients with B7-1-positive glomerular disease.Entities:
Mesh：
Substances：
Year: 2013 PMID： 24206430 PMCID： PMC3951406 DOI： 10.1056/NEJMoa1304572
Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245